Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V3G CH848 Pr-NP1
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
V3G CH848 Pr-NP1 is an investigational prophylactic HIV-1 vaccine prime immunogen developed by the National Institute of Allergy and Infectious Diseases. It is a ferritin nanoparticle displaying eight copies of a native-like HIV-1 envelope trimer designed to initiate B-cell responses that can mature into V3-glycan-specific broadly neutralizing antibodies against HIV-1. It is being evaluated in a first-in-human Phase 1 prime-boost study in adults without HIV, with later boosting by the distinct mRNA-LNP immunogen V3G CH848 mRNA-Tr2. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05903339))
- Other names
- V3G + CH848 + Pr-NP1
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on V3G CH848 Pr-NP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V3G CH848 Pr-NP1.